Press Enter to search · ESC to close

Macro

Pfizer Licenses Three in vivo CAR-T Programs from Starna Therapeutics in Deal Worth Up to $2.3B

Pfizer on November 18 signed an exclusive licensing agreement with Starna Therapeutics for three pre-IND in vivo CAR-T programs targeting autoimmune diseases. Pfizer gains exclusive development, manufacturing and commercialization rights outside Greater China. The deal includes milestone payments of up to $2.3 billion.

Share

Related News

新云社 share card
Long-press image above → Save to Photos / Share
Pitch us Feedback